| products | technology | press | careers | ||||||||||||||
 |
|||||||||||||||||
 |
|||||||||||||||||
 |
 |
 |
 |
||||||||||||||
|
Wave 80 awarded $7.5 million NIH contract for HIV rapid virus testing. Next-generation point-of-care molecular diagnostic system meets challenges of detecting acute infection, monitoring recipients of candidate vaccines, and diagnosing infants born to HIV-infected mothers. October 28, 2009 Wave 80 chief executive to address microsystems commercialization conference in Chongqing, China. Talk will highlight evolving challenges and opportunities in global health. October 14, 2009 Wave 80, Magnisense partner in infectious disease diagnostics and patient monitoring. Collaboration to explore new ways of using magnetic detection in high-performance enclosed-cartridge-format assays. March 5, 2009 Wave 80 presents poster at multiple sclerosis meeting. Exploring new methods of optimizing therapies for optimizing therapies. January 3, 2009 Wave 80 initiates new program in biomarker-based stroke patient stratification. New approach to guiding therapy holds promise for significantly improving patient outcomes in acute ischemic stroke. July 9, 2008 Wave 80, Siemens team up on HIV viral load measurement. With NIH support, initiative seeks to develop innovative tools for guiding antiretroviral therapy. October 19, 2007 Wave 80 malaria diagnostic selected for oral presentation at prestigious |
|||||||||||||||||
|
Wave 80 Biosciences is a research-driven medical technologies company developing innovative molecular assay methods, novel techniques for leukocyte analysis and fractionation, and next-generation clinical laboratory testing systems. The centerpiece of Wave 80’s product pipeline is the EOSCAPE family of high-performance, compact-form-factor systems for measurement of high-clinical-value biomarkers in peripheral blood. Wave 80 is headquartered in San Francisco, California. |
|||||||||||||||||
copyright 2009 wave 80 biosciences, inc. san francisco, california |
|||||||||||||||||